Page 62 - Read Online

Almeida et al. J Cancer Metastasis Treat 2021;7:57 https://dx.doi.org/10.20517/2394-4722.2021.108 Page 9 of 10

REFERENCES
1. Grigoriu B, Berghmans T, Meert AP. Management of EGFR mutated nonsmall cell lung carcinoma patients. Eur Respir J
2015;45:1132-41. DOI PubMed
2. Boehrer S, Adès L, Braun T, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood
2008;111:2170-80. DOI PubMed
3. Project GENIE Consortium. AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov
2017;7:818-31. DOI PubMed PMC
4. Loriaux MM, Levine RL, Tyner JW, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
Blood 2008;111:4788-96. DOI PubMed PMC
5. Sun JZ, Lu Y, Xu Y, et al. Epidermal growth factor receptor expression in acute myelogenous leukaemia is associated with clinical
prognosis. Hematol Oncol 2012;30:89-97. DOI PubMed
6. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid
leukemia. Blood 2005;106:2841-8. DOI PubMed PMC
7. Boehrer S, Adès L, Galluzzi L, et al. Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid
leukemia: a preclinical comparison. Biochem Pharmacol 2008;76:1417-25. DOI PubMed
8. Lindhagen E, Eriksson A, Wickström M, et al. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in
acute myeloblastic leukaemia. Eur J Haematol 2008;81:344-53. DOI PubMed
9. Onetto-Pothier N, Aumont N, Haman A et al. IL-3 inhibits the binding of GM-CSF to AML blasts, but the two cytokines act
synergistically in supporting blast proliferation. Leukemia 1990;4:329-36. PubMed
10. Nievergall E, Ramshaw HS, Yong AS, et al. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML
progenitor and stem cells. Blood 2014;123:1218-28. DOI PubMed
+
11. Radpour R, Riether C, Simillion C, Höpner S, Bruggmann R, Ochsenbein AF. CD8 T cells expand stem and progenitor cells in
favorable but not adverse risk acute myeloid leukemia. Leukemia 2019;33:2379-92. DOI PubMed
12. Mahmud H, Kornblau SM, Ter Elst A, et al. Epidermal growth factor receptor is expressed and active in a subset of acute myeloid
leukemia. J Hematol Oncol 2016;9:64. DOI PubMed PMC
13. Miranda MB, Duan R, Thomas SM, et al. Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia 2008;22:1624-7. DOI
PubMed PMC
14. Noh EK, Kim H, Park MJ, et al. Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia
cell line. Leuk Res 2010;34:1501-5. DOI PubMed
15. Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 2009;16:281-
94. DOI PubMed PMC
16. Cao ZX, Guo CJ, Song X, et al. Erlotinib is effective against FLT3-ITD mutant AML and helps to overcome intratumoral
heterogeneity via targeting FLT3 and Lyn. FASEB J 2020;34:10182-90. DOI PubMed
17. Boehrer S, Galluzzi L, Lainey E, et al. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid
leukemia. Cell Cycle 2011;10:3168-75. DOI PubMed
18. Deangelo DJ, Neuberg D, Amrein PC, et al. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.
Leuk Res 2014;38:430-4. DOI PubMed PMC
19. Abou Dalle I, Cortes JE, Pinnamaneni P, et al. A pilot phase II study of erlotinib for the treatment of patients with relapsed/refractory
acute myeloid leukemia. Acta Haematol 2018;140:30-9. DOI PubMed
20. Sayar H, Czader M, Amin C, Cangany M, Konig H, Cripe LD. Pilot study of erlotinib in patients with acute myeloid leukemia. Leuk
Res 2015;39:170-2. DOI PubMed
21. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21-6. DOI PubMed
22. Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer
strategies. Int J Cancer 2005;117:883-8. DOI PubMed
23. Russo A, Franchina T, Ricciardi GR, et al. Influence of EGFR mutational status on metastatic behavior in non squamous non small cell
lung cancer. Oncotarget 2017;8:8717-25. DOI PubMed PMC
24. Jorissen R. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53. DOI PubMed
25. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16. DOI
PubMed
26. Rayego-Mateos S, Rodrigues-Díez R, Morgado-Pascual JL, et al. Connective tissue growth factor is a new ligand of epidermal growth
factor receptor. J Mol Cell Biol 2013;5:323-35. DOI PubMed
27. Sanders JM, Wampole ME, Thakur ML, Wickstrom E. Molecular determinants of epidermal growth factor binding: a molecular
dynamics study. PLoS One 2013;8:e54136. DOI PubMed PMC
28. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Letters
1999;447:227-31. DOI PubMed
29. Chen J, Zeng F, Forrester SJ, Eguchi S, Zhang MZ, Harris RC. Expression and function of the epidermal growth factor receptor in
physiology and disease. Physiol Rev 2016;96:1025-69. DOI PubMed
30. Sasaki T, Hiroki K, Yamashita Y. The role of epidermal growth factor receptor in cancer metastasis and microenvironment. Biomed
Res Int 2013;2013:546318. DOI PubMed PMC
31. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.